Imaging in targeted delivery of therapy to cancer
- 1 September 2009
- journal article
- review article
- Published by Springer Nature in Targeted Oncology
- Vol. 4 (3) , 201-217
Abstract
We review the current status of imaging as applied to targeted therapy with particular focus on antibody-based therapeutics. Antibodies have high tumor specificity and can be engineered to optimize delivery to, and retention within, the tumor. Whole antibodies can activate natural immune effector mechanisms and can be conjugated to β- and α-emitting radionuclides, toxins, enzymes, and nanoparticles for enhanced therapeutic effect. Imaging is central to the development of these agents and is used for patient selection, performing dosimetry and assessment of response. γ- and positron-emitting radionuclides may be used to image the distribution of antibody-targeted therapeutics While some radionuclides such as iodine-131 emit both β and γ radiation and are therefore suitable for both imaging and therapy, others are more suited to imaging or therapy alone. Hence for radionuclide therapy of neuroendocrine tumors, patients can be selected for therapy on the basis of γ-emitting indium-111-octreotide imaging and treated with β-emitting yttrium-90-octreotate. Positron-emitting radionuclides can give greater sensitivity that γ-emitters but only a single radionuclide can be imaged at one time and the range of radionuclides is more limited. The multiple options for antibody-based therapeutic molecules, imaging technologies and therapeutic scenarios mean that very large amounts of diverse data are being acquired. This can be most effectively shared and progress accelerated by use of common data standards for imaging, biological, and clinical data.Keywords
This publication has 184 references indexed in Scilit:
- A Phase I Trial of Radioimmunotherapy with 131I-A5B7 Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced Gastrointestinal CarcinomasClinical Cancer Research, 2009
- Use of antibodies and immunoconjugates for the therapy of more accessible cancersAdvanced Drug Delivery Reviews, 2008
- Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugsNature Clinical Practice Oncology, 2008
- Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT®)European Journal of Nuclear Medicine and Molecular Imaging, 2006
- In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fractionNuclear Medicine and Biology, 2006
- Engineered antibody fragments and the rise of single domainsNature Biotechnology, 2005
- The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructsNuclear Medicine and Biology, 2005
- Synthesis of 2′-deoxy-2′-[18F]fluoro-β-D-arabinofuranosyl nucleosides, [18F]FAU, [18F]FMAU, [18F]FBAU and [18F]FIAU, as potential PET agents for imaging cellular proliferationNuclear Medicine and Biology, 2003
- Radiation Absorbed Dose Estimation for 90 Y-DOTA-biotin with Pretargeted NR-LU-10/StreptavidinCancer Biotherapy and Radiopharmaceuticals, 1999
- Tumor Localization of Radio-Labeled Antibodies against Carcinoembryonic Antigen in Patients with CarcinomaNew England Journal of Medicine, 1980